We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
Cap. Flow
+$71.5M
Cap. Flow %
2.43%
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$85.5M
2
QURE icon
uniQure
QURE
+$52M
3
LH icon
Labcorp
LH
+$50.7M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$46.9M
5
IFRX icon
InflaRx
IFRX
+$40.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$78.7M
2
PBYI icon
Puma Biotechnology
PBYI
+$74.6M
3
PEN icon
Penumbra
PEN
+$67.6M
4
ABT icon
Abbott
ABT
+$39.2M
5
RGNX icon
Regenxbio
RGNX
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.2%
2 Miscellaneous 1.77%
3 Financials 1.03%
4 Technology 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGRY icon
51
Surgery Partners
SGRY
$1.79B
$9.26M 0.31%
+621,300
New +$10.4M
STIM icon
52
Neuronetics
STIM
$224M
$7.98M 0.27%
+300,000
New +$8.16M
LUMO
53
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$7.67M 0.26%
179,083
-49,161
-22% -$2.25M
IMUX icon
54
Immunic
IMUX
$210M
$7.5M 0.25%
+2,738
New +$6.33M
INSP icon
55
Inspire Medical Systems
INSP
$1.78B
$7.13M 0.24%
+200,000
New +$6.46M
ONC
56
BeOne Medicines Ltd
ONC
$41.5B
$6.2M 0.21%
40,300
+300
+0.8% +$53.5K
CTMX icon
57
CytomX Therapeutics
CTMX
$699M
$6M 0.2%
262,400
-72,280
-22% -$1.85M
NVTA
58
DELISTED
Invitae Corporation
NVTA
$5.97M 0.2%
812,240
-1,327,280
-62% -$8.82M
SENS icon
59
Senseonics Holdings Inc
SENS
$493M
$5.42M 0.18%
+65,896
New +$4.72M
SRPT icon
60
Sarepta Therapeutics
SRPT
$2.2B
$4.11M 0.14%
+31,100
New +$2.93M
EIDX
61
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$3.88M 0.13%
+191,000
New +$4M
UBX
62
DELISTED
Unity Biotechnology
UBX
$3.77M 0.13%
+25,040
New +$3.66M
ACRS icon
63
Aclaris Therapeutics
ACRS
$885M
$2.13M 0.07%
106,820
– –
VCEL icon
64
Vericel Corp
VCEL
$2.1B
$1.75M 0.06%
+180,873
New +$2.25M
ATYR
65
aTyr Pharma
ATYR
$53M
$1.72M 0.06%
134,642
– –
OVID icon
66
Ovid Therapeutics
OVID
$547M
$951K 0.03%
121,950
-38,768
-24% -$333K
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$427K 0.01%
25,800
+5,800
+29% +$88.4K
IHF icon
68
iShares US Healthcare Providers ETF
IHF
$1.23B
$367K 0.01%
10,435
– –
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$356K 0.01%
+7,170
New +$347K
FLXN
70
DELISTED
Flexion Therapeutics, Inc.
FLXN
$343K 0.01%
13,260
+3,330
+34% +$86.4K
SAGE
71
DELISTED
Sage Therapeutics
SAGE
$340K 0.01%
+2,170
New +$341K
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$15.9B
$274K 0.01%
+1,590
New +$260K
NVRO
73
DELISTED
NEVRO CORP.
NVRO
$271K 0.01%
+3,400
New +$282K
AMED
74
DELISTED
Amedisys
AMED
$233K 0.01%
+2,725
New +$200K
BHC icon
75
Bausch Health
BHC
$2.36B
$208K 0.01%
+8,930
New +$185K
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2018 Portfolio in Review

As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
  • Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
  • Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
  • Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
  • Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
  • Redmile Group opened 27 new positions and closed 12 in Q2 2018.
  • Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.